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Post-thrombotic syndrome (PTS) is the most frequent chronic complication of acute deep vein throm-
bosis (DVT). However, gaps in our current understanding of the risk factors, diagnostic criteria, pre-
ventive strategies, and even treatment modalities for PTS prevent clinicians from employing measures
that could reduce the occurrence of this disorder and the associated morbidity. This review provides an
overview of the important elements of PTS, including recent multifaceted aspects related to its deﬁnition,
pathophysiology, risk factors, prevention and management.
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Post-thrombotic syndrome (PTS) is the most frequent chronic
complication of acute deep vein thrombosis (DVT), occurring in
20–40% of patients with DVT and severe symptoms developing in
5–10% of such patients [1–3]. PTS has a signiﬁcant negative impact
on quality of life (QOL) outcomes and health care costs [4]. PTS can
be diagnosed clinically after a previous objective diagnosis of DVT
in the absence of speciﬁc laboratory imaging or functional tests
[3]. The signs and symptoms of PTS vary from patient to patient
and may include edema, heaviness, leg pain, eczema, hy-
perpigmentation, lipodermatosclerosis, and venous ulcers. How-
ever, PTS and primary valvular insufﬁciency share signs and
symptoms of chronic venous insufﬁciency, making correct diag-
nosis of PTS difﬁcult. The present review focuses on the features of
PTS, reviewing its deﬁnition, pathophysiology, risk factors, diag-
nosis, prevention and management.2. Deﬁnition of PTS
Despite increasing awareness of PTS as a common and im-
portant complication of DVT, there is no gold standard objective
test to establish its presence, and PTS is diagnosed primarily on the
basis of typical symptoms and clinical signs in limbs affected by
DVT. Several scoring systems or classiﬁcations for grading the se-
verity of PTS have been proposed [3], including the Villalta scale
[5], Ginsberg measure [6] and Brandjes score [7]. On the other
hand, the Widmer [8] and Clinical, Etiologic, Anatomic, and Pa-
thophysiologic (CEAP) [9] classiﬁcations, and the Venous Clinical
Severity Score (VCSS) [10] were originally developed for patients
with chronic venous insufﬁciency (CVI), but can be applied to
cases of PTS.
2.1. Villalta scale
The Villalta scale was designed speciﬁcally for patients with
PTS and introduced in an abstract in 1994 as a disease-speciﬁc
assessment questionnaire for diagnosis and classiﬁcation of the
severity of PTS. The Villalta scale (Table 1) assesses ﬁve symptoms
(pain, cramps, heaviness, paresthesia, pruritus) and six clinicalTable 1
Villata scale [5].
Symptoms/clinical signs None Mild Moderate Severe
Symptoms 0 points 1 point 2 points 3 points
Pain 0 points 1 point 2 points 3 points
Cramps 0 points 1 point 2 points 3 points
Heaviness 0 points 1 point 2 points 3 points
Paresthesia 0 points 1 point 2 points 3 points
Pruritus 0 points 1 point 2 points 3 points
Clinical signs 0 points 1 point 2 points 3 points
Pretibial edema 0 points 1 point 2 points 3 points
Skin induration 0 points 1 point 2 points 3 points
Hyperpigmentation 0 points 1 point 2 points 3 points
Redness 0 points 1 point 2 points 3 points
Venous ectasia 0 points 1 point 2 points 3 points
Pain on calf compression 0 points 1 point 2 points 3 points
Venous ulcer Absent Presentsigns (pretibial edema, skin induration, hyperpigmentation, red-
ness, venous ectasia, pain on calf compression). Each variable has a
4-point scale ranging from 0 (absent) to 3 (severe). PTS is diag-
nosed if the Villalta score is Z5 or if a venous ulcer is present. A
score of 5–9 is categorized as mild, 10–14 as moderate, and Z15 as
severe disease. The subcommittee for Control of Anticoagulation of
the International Society for Thrombosis and Hemostasis has re-
commended the Villalta scale as the most appropriate method for
diagnosis of PTS [11]. Furthermore, a recent systematic review of
various scoring systems for PTS revealed that the Villalta score,
combined with a venous disease-speciﬁc quality of life ques-
tionnaire, was the most suitable gold standard for diagnosis and
classiﬁcation of PTS [12].
2.2. Ginsberg measure
The Ginsberg measure was designed on the basis of persistence
of symptoms or development of new symptoms 6 months after an
initial DVT. The recommended criteria for the Ginsberg measure
are as follows:
■ Persistent swelling and leg pain for 1 month after DVT
■ Pain and swelling developing 6 months after DVT
■ Relieved by rest and elevation
Kahn et al. carried out a clinical study comparing the Villalta
scale and the Ginsberg measure, and found that the proportion of
patients classiﬁed as having PTS was almost 5-fold higher with the
Villalta scale than with the Ginsberg measure, and that the
agreement between the two measures was poor at 1 year after
DVT [13]. They concluded that the Ginsberg measure identiﬁes
more severe disease.2.3. Brandjes score
The Brandjes score was developed to assess the effect of com-
pression stockings on patients with symptomatic proximal DVT.
The Brandjes score is composed of objective symptoms and sub-
jective signs, and these variables are graded as absent or present
(Table 2). A diagnosis of mild-moderate PTS is made if the score is
3 or higher (including one objective criterion), whereas a diagnosis
of severe PTS is established if the score is 4 or more.Table 2
Brandjes score [7].
Subjective criteria Objective criteria
Symptoms Score Signs Score
Spontaneous pain in calf 1 Calf circumference increased
by 1 cm
1
Spontaneous pain in thigh 1 Ankle circumference in-
creased by 1 cm
1
Calf pain on standing/walking 1 Pigmentation 1
Thigh pain on standing/walking 1 Venectasia 1
Edema of foot/calf 1 Newly formed varicosis 1
Heaviness of foot/calf 1 Phlebitis 1
Spontaneous pain and pain on
walking/standing
1 Venous ulcer 4
Impairment of daily activities 1
Table 3
Widmer classiﬁcation [8].
Stage Symptoms
1 Ankle ﬂare
Subclinical edema
2 Edema
Pigmentation
Lipodermatosclerosis
White (skin) atrophy
3 Leg ulcer
Leg ulcer in the past
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The Widmer classiﬁcation was originally developed for grading
the severity of CVI, but has also been utilized for PTS. This classi-
ﬁcation grades patients into classes I, II and III (Table 3) based
mainly on clinical signs, and is still widely used in German-
speaking countries.
2.5. CEAP classiﬁcation
The CEAP classiﬁcation was developed to categorize chronic
venous disease (CVD) according to clinical signs (C), etiology (E),
anatomic distribution (A), and pathophysiology. This classiﬁcation
subdivides patients into eight classes according to the clinical se-
verity (Table 4). Use of the CEAP classiﬁcation is especially wide-
spread among physicians specializing in vascular conditions, and
can also be used for assessment of PTS. However, these tools lack a
consensus “cut-off” for classiﬁcation of the PTS category. For ex-
ample, while Yamaki et al., using the CEAP classiﬁcation, deﬁned a
clinical signs score of Z4 as diagnostic for PTS [14], others have
used a score of Z3 for the PTS category [15,16]. In a prospective
study of 40 limbs in 34 patients with established PTS, Lattimer
et al. found a good correlation between the Villalta scale, VCSS and
CEAP classiﬁcations [17].
2.6. VCSS
The VCSS was developed from elements of the CEAP classiﬁ-
cation, but was not designed to replace the latter. The VCSS is
evaluative and longitudinal, while the CEAP classiﬁcation is de-
scriptive and relatively static (Table 5). Thus, it is designed to give
additional weight to more severe manifestations of CVD (CEAP
clinical class 4–6). The VCSS has been used and evaluated in
multiple studies with varied results [18,19]. However, there is no
standard VCS score for diagnosing or grading the severity of PTS.
Furthermore, Meissner et al. found that the component scores for
pain, inﬂammation, and pigmentation showed signiﬁcant inter-
observer variability, even if the VCSS showed a good correlation
with the CEAP classiﬁcation [20]. Accordingly, the VCSS is not used
to diagnose the presence of PTS but rather for measurement ofTable 4
CEAP clinical classiﬁcation [9].
Class Signs
C0 No visible or palpable signs of venous disease
C1 Telangiectasias or reticular veins
C2 Varicose veins; distinguished from reticular veins by a diameter of 3 mm
or more
C3 Edema
C4a Pigmentation or eczema
C4b Lipodermatosclerosis or atrophic blanche
C5 Healed venous ulcer
C6 Active venous ulcerdisease severity.3. Pathophysiology of PTS
The pathophysiologic mechanism whereby PTS develops after
DVT is not fully understood. Clinical observations have shown that
a blood clot forming in the deep veins of the lower extremity can
cause inﬂammation and interrupt venous blood ﬂow to the heart,
causing severe damage to the vein valves, making them leaky and
allowing retrograde blood ﬂow to the ankle. Such venous blood
ﬂow interruption and retrograde blood ﬂow can cause venous
hypertension, thereby leading to hyperpigmentation, corona
phlebectatica, lipodermatosclerosis or ulceration. These processes
include leukocyte activation, adhesion and migration through the
basement membrane with release of growth factors and proteases
[21].
Experimental observations have revealed that leukocytes
mediate the release and activation of metalloproteinase 2 (MMP-
2) and MMP-9, as well as promoting vein wall ﬁbrosis. Vein wall
remodeling after DVT is similar to wound healing, and is asso-
ciated with increased expression of the procollagen gene and total
collagen [22]. This is associated with increased early expression of
MMP-9, followed by MMP-2 expression and activity after DVT
resolution. Another study has shown that post-thrombotic vein
wall remodeling is impaired in cystine-cystine receptor 7 (CCR7)
(/) mice, which have a proﬁbrotic phenotype, is dependent on
a thrombotic mechanism, and is mediated by circulating CCR7(þ)
cells [23]. CCR7(þ) signaling may play an important role in posi-
tive vein wall remodeling after a thromboembolic event.4. Factors associated with the risk of developing PTS
The factors associated with the risk of developing PTS are not
well understood. For this reason, it is difﬁcult to reliably identify
which patients are likely to develop PTS in the acute phase of DVT.
4.1. Patient characteristics at initial onset of DVT
Among 1916 patients participating in the Multiple Environ-
mental and Genetic Assessment (MEGA) study of risk factors for
DVT, the 1-year cumulative incidence of PTS was 25% with a cu-
mulative incidence of 7% for severe PTS [24]. Compared to male
patients, women were at higher risk of PTS [risk ratio (RR) 1.5, 95%
conﬁdence interval (CI) 1.3–1.8] [24]. Similarly, obese patients had
a 1.5-fold (RR 1.5, 95% CI 1.2–1.9) increased risk of PTS compared
with individuals with a normal body mass index (BMI) [24].
However, the role of higher BMI in the development of PTS is still
being debated [12]. Patients with varicose veins also had an in-
creased risk of PTS (RR 1.5, 95% CI 1.2–1.8). Concerning the initial
anatomic distribution of DVT, patients who had thrombus in the
ilio-femoral venous segment had 1.3-fold risk of PTS compared
with those who had femoro-popliteal DVT (RR 1.3, 95% CI 1.1–1.6)
[24], whereas another study revealed a high risk of developing PTS
in patients who had distal DVT [25]. In contrast, older patients
were less likely to develop PTS (RR 0.6, 95% CI 0.4–0.9) [24].
Moreover, the presence of factor V Leiden or prothrombin gene
mutation is reportedly an independent predictor of a lower risk of
PTS [26].
4.2. Recurrent DVT
Several studies have identiﬁed ipsilateral recurrent DVT as a
strong risk factor for PTS [27–30]. Ipsilateral recurrent DVT was
found to be associated with a 6–10-fold risk of PTS. Several factors
Table 5
VCSS [10].
Descriptor None: 0 Mild: 1 Moderate: 2 Severe: 3
Pain None or focal Occasional pain or other discomfort Daily pain or other discomfort Daily pain or discomfort
Varicose veins (44 mm diameter) Few, scattered: branch varicosities Conﬁned to calf or thigh Involves calf and thigh
Venous edema Limited to foot and ankle area Extends above ankle but below
knee
Extends to knee and above
Skin pigmentation Limited to perimalleolar area Diffuse over lower third of calf Wider distribution above lower third of
calf
Inﬂammation Limited to perimalleolar area Diffuse over lower third of calf Wider distribution above lower third of
calf
Induration Limited to perimalleolar area Diffuse over lower third of calf Wider distribution above lower third of
calf
Active ulcer number 0 1 2 Z3
Active ulcer duration N/A o3 months 43 months but o1 year Not healed for 41 year
Active ulcer size N/A Diameter o2 cm Diameter 2–6 cm Diameter 46 cm
Use of compression therapy 0 Not used 1 Intermittent use of stockings 2 Wears stockings most days 3 Full compliance: stockings
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ing the course of treatment. Hull et al. found that subtherapeutic
anticoagulation early in the course of treatment (ﬁrst 24 h) in-
creased the risk of recurrent VTE events 15-fold [31]. Compared to
unfractionated heparin, greater thrombus resolution followed by
reduction in post-thrombotic morbidity was found with the use of
low-molecular-weight heparin (LMWH) in the early stage of DVT
treatment [32]. Moreover, Young et al. reported that recurrent DVT
risk was increased [hazard ratio (HR) 2.2] in patients in whom
residual thrombus was found on follow-up duplex ultrasound [33].
Recently, a direct thrombin inhibitor (Dabigatran) and factor Xa
inhibitor (Apixaban) have been proven to facilitate quicker clot
lysis and recanalization than warfarin in an experimental model.
Future studies investigating these effects of direct oral antic-
oagulants (DOAC) on clot lysis in humans are warranted [34–36].
4.3. Duration and intensity of oral anticoagulation
The duration of anticoagulation also affects the incidence of
recurrent DVT. Recurrent VTE is expected to develop in at least 30%
of patients after receiving oral anticoagulant therapy for 3–6
months [37,38]. Schulman et al. carried out a multicenter trial
comparing six weeks of oral anticoagulation with six months of
the same treatment in patients with a ﬁrst episode of DVT, and
found that the latter resulted in lower recurrence of DVT than the
former [37]. Patients with permanent risk factors for VTE (e.g.
active cancer, immobilization, antiphospholipid syndrome) and
those with unprovoked VTE had a higher incidence of VTE than
those with transient risk factors including hormone replacement
therapy, minor injury, pregnancy and long-distance travel [38].
Kahn et al. found no signiﬁcant difference in the risk of developing
PTS between patients who had warfarin therapy with an inter-
national normalized ratio (INR) of 1.5–1.9 and those with an INR of
2.0–3.0 [39]. In contrast, Chitsike et al. reported that patients who
had subtherapeutic anticoagulation (INR o2) had a higher risk of
developing PTS than those who had therapeutic oral anticoagulant
therapy [odds ratio (OR) 1.88 95% CI 1.15–3.07] [40].
4.4. Venous abnormalities detected by duplex ultrasound
Residual venous thrombus and development of venous reﬂux
increase the risk of PTS development over time. In a study invol-
ving 120 lower extremities of 105 patients who had a ﬁrst episode
of DVT, Labropoulos et al. reported that limbs with both reﬂux and
obstruction were more likely to develop skin damage than those
with reﬂux or obstruction alone [41]. Comerota et al. investigated
the relationship between residual thrombus and symptoms of PTS
and found a direct and signiﬁcant correlation of CEAP clinical class(r2¼0.74) and Villalta score (r2¼0.61) with residual thrombus,
suggesting that residual thrombus is associated with an increased
risk of PTS [42]. In contrast, Yamaki et al. reported that the pre-
sence of reﬂux, as reﬂected by elevated peak reﬂux velocity in the
axial deep veins, mainly in the popliteal (425.4 cm/s, OR 60.32)
and (424.5 cm/s, OR 25.77) femoral veins was a strong in-
dependent predictor of advanced PTS [43]. However, they did not
ﬁnd any signiﬁcant correlation between progression of PTS
symptoms and reﬂux time, which is now considered the gold
standard for diagnosis of venous reﬂux. Latella et al. also found
that valvular reﬂux in the popliteal vein was independently asso-
ciated with moderate to severe PTS (OR 2.72 compared with no or
mild PTS, 95% CI 1.25, 5.90) [44].
4.5. Abnormal biomarkers
Several investigators have tested the possible correlation be-
tween elevated D-dimer levels and development of PTS. Latella
et al. found that the mean D-dimer level at 4 months after DVT was
signiﬁcantly higher in patients who developed PTS than in those
who did not [44]. In contrast, Galanaud et al. evaluated D-dimer
levels after discontinuation of anticoagulants but found no sig-
niﬁcant association with the development of PTS [45]. The asso-
ciation between ﬁbrinogen level and PTS development has also
been studied by several investigators, but no correlation was evi-
dent [46,47].
With regard to other markers predictive of PTS, Rabinovich
et al. conducted a systematic review of the association between
inﬂammatory biomarkers and PTS. However, the results were
conﬂicting, and only intercellular adhesion molecule (ICAM)-1 was
suggested to be a promising marker for further investigation [48].
4.6. Hemodynamic changes in patients with PTS
Using air plethysmography (APG), Lattimer et al. compared the
Villalta scale with the VCSS, CEAP classiﬁcation and venous he-
modynamics using the venous ﬁlling index (VFI) [17]. They found a
meaningful correlation of VFI with the Villalta (r¼0.499) scale and
VCSS (r¼0.480) and concluded that VFI may provide a clinically
meaningful venous hemodynamic parameter for evaluation of PTS.
In the presence of proximal venous occlusion, however, VFI ob-
tained by APG may underestimate the magnitude of venous reﬂux
[49].
Several investigators have applied various plethysmographic
methods for detection of arterial perfusion, and found increased
resting arterial perfusion and reduced arterial inﬂow during the
hyperemic response in patients with severe chronic venous dis-
orders [50–53]. These ﬁndings lend support to the view that
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venous and arterial systems of the lower extremities at the mi-
crocirculation level. The disadvantages of plethysmographic ex-
amination include the use of different measuring systems for as-
sessment of venous and arterial inﬂows. Accordingly, little is
known about the venous and arterial interrelationship in patients
with chronic venous diseases revealed using various forms of
plethysmography.
Changes in calf muscle deoxygenated hemoglobin (HHb) levels
have been investigated by several authors using near-infrared
spectroscopy (NIRS). Hosoi et al. ﬁrst applied this modality for
assessment of hemodynamics in patients with CVI. They used the
ambulatory venous retention index (AVRI) obtained from serial
HHb changes as a parameter, and found that NIRS was useful for
evaluation of ambulatory venous dysfunction [54]. They then
studied symptomatic PTS, and found that the AVRI was correlated
well with clinical severity [55]. Yamaki et al. also found that a
higher retention index predicted the development of severe PTS
symptoms [56,57].
Later, Yamaki et al. developed a new method for identifying
changes in calf muscle oxygenated hemoglobin (O2Hb) and HHb
using NIRS in patients with CVD [58]. Using this protocol, they
found signiﬁcant differences in O2Hb and HHb changes between
patients with and those without established PTS as follows:
■ On standing, the time taken until the maximum increase in
O2Hb (TO2Hbst) and the oxygenation index (HbDst) were sig-
niﬁcantly decreased in patients with PTS in comparison to those
without.
■ During exercise, venous expulsion (ΔHHbEex) was signiﬁcantly
decreased and ΔHHbRex was signiﬁcantly increased in patients
with PTS.
■ Decreases in the oxygenation index during exercise (HbDex)
were more pronounced in patients with PTS [59]
They also found that TO2Hbstr48 s was the only NIRS-derived
predictor of PTS at the 6-month follow-up point (OR 53.73, 95% CI:
8.43–342.41). They concluded that NIRS-derived O2Hb appeared to
reveal the earliest change in PTS, rather than the change in HHb,
during follow-up of patients with DVT [60].5. Prevention of PTS
To prevent the development of PTS, three main methods have
been applied to date: thromboprophylaxis, elastic compression
stockings (ECSs) and thrombolysis.5.1. Thromboprophylaxis
A current existing guideline for antithrombotic therapy re-
commends anticoagulation for 3 months over (i) treatment for a
shorter period (Grade 1B), (ii) treatment for a longer time-limited
period (e.g., 6, 12, or 24 months) (Grade 1B), or (iii) extended
therapy (no scheduled stop date) (Grade 1B) [61]. However, the
risk of recurrent DVT increases over time after withdrawal of oral
anticoagulants. In a randomized study that included 897 patients
who were assessed at the 10-year follow-up point, Schulman et al.
found no additional beneﬁt of warfarin for 6 months over a shorter
6-week administration period [62]. In comparison with warfarin,
González-Fajardo et al. found that LWMH was associated with a
higher frequency of thrombus regression and a lower prevalence
of recurrent VTE and PTS [63].5.2. Elastic compression stockings
The application of ECSs after DVT is widely accepted to prevent
the development of PTS. Compression therapy is believed to re-
duce leg edema, promote venous blood return and improve ve-
nous pump function, and compression therapy has been the ﬁrst
choice for prevention of PTS [64]. Several randomized clinical trials
(RCTs) have supported the use of ECSs for PTS prevention. Brandjes
et al. stratiﬁed patients into ECS and no-stocking groups for as-
sessment of outcome after DVT, and reported a 50% reduction in
the incidence of PTS [7]. Previous systematic reviews of the ef-
fectiveness of ECS reported a 48–54% relative risk reduction [65–
67]. In contrast, Kahn et al. conducted multicenter randomized
placebo-controlled trial of active versus placebo ECSs applied for
2 years for prevention of PTS [68]. The primary outcome of the
study was PTS diagnosed at 6 months or later using Ginsberg's
criteria (leg pain and swelling for Z1 month). The cumulative
incidence of PTS was 14.2% for active ECS versus 12.7% for placebo
ECS (HR 1.13, 95% CI 0.73–1.76; p¼0.58), and concluded that ECS
did not prevent PTS after a ﬁrst episode of proximal DVT.
In a recent systematic review addressing the effectiveness of
ECS including 5 RCTs, Bernstein reported that the HR for PTS with
ECSs was 0.69 (95% CI 0.47–1.02). All 5 studies also suggested no
effect of ECSs on VTE recurrence (RR 0.88; 95% CI, 0.63–1.24) [69].
Accordingly, a recent guideline for antithrombotic therapy does
not recommend routine use of ECSs to prevent PTS in patients
with acute DVT (Grade 2B) [61].
5.3. Thrombolysis
Active thrombus removal may improve venous blood circula-
tion, preserve valvular function, and thus reduce the risk of PTS.
Because patients with extensive DVT, particularly these with ilio-
femoral DVT, have a higher risk of developing PTS than those with
without, early clot lysis may lead to reduction of post-thrombotic
sequelae [70,71]. Previous studies addressing the efﬁcacy of sys-
temic thrombolysis found a signiﬁcant improvement in clot lysis. A
review by Watson and Armon reported a signiﬁcant improvement
in complete clot lysis (RR 4.14, 95% CI 1.22–14.01), which was
maintained at longer-term follow-up (RR 2.71, 95% CI 1.84–3.99)
[72]. Other trials have demonstrated a lower prevalence of PTS
development in patients who received plasminogen activator
compared with these who received heparin [73,74].
To obtain successful clot lysis, a plasminogen activator needs to
act on a large clot surface [75]. For this reason, currently, en-
dovascular therapies have replaced previously attempted systemic
thrombolytic therapies because of their higher efﬁciency, and
several RCTs have been published. An improved QOL was also re-
ported in patients receiving catheter-directed thrombolysis (CDT)
compared with these receiving anticoagulation alone [76].
Elsharawy et al. carried out a randomized study comparing CDT
with standard anticoagulation in patients with ilio-femoral DVT,
and found a signiﬁcantly higher proportion of complete clot lysis
in patients who received CDT than in those who received antic-
oagulation (72% vs. 12%, po0.001) [77]. The TORPEDO trial re-
vealed a signiﬁcant reduction of VTE recurrence (2.3% vs. 14.8%,
p¼0.003) and PTS incidence (3.4% vs. 27.2%, P¼0.001) at the
6-month follow-up point in patients treated with CDT. The CaVenT
study evaluated 24-month outcome data in patients with ilio-fe-
moral DVT who were randomly assigned to conventional treat-
ment alone or conventional treatment with additional CDT [78].
After 24 months of follow-up, the incidence of PTS was sig-
niﬁcantly decreased in patients allocated additional CDT relative to
those who received conventional treatment (41.1% vs. 55.6%,
p¼0.047). This corresponded to an absolute risk reduction of
14 4% (95% CI 0.2–27.9), and the number who required treatment
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complications were more frequent in the treatment group than in
the control group (p¼0.003). Notably, the CaVenT study evaluated
outcome during an extended duration of follow-up [79]. At the
5-year follow-up point, 37 patients (43%; 95% CI 33–53) allocated
to catheter-directed thrombolysis developed PTS, compared with
63 (71%; 95% CI 61–79) allocated to the control group (po0.0001),
corresponding to an absolute risk reduction of 28% (95% CI 14–42)
and a number who required treatment of 4 (95% CI 2–7). Despite
these favorable results with the use of CDT for prevention of PTS,
this therapy failed to improve QOL [79]. The ATTRACT study is a
health-sponsored, Phase III, multicenter RCT designed to compare
pharmacomechanical catheter-directed thrombolysis (PCDT)þ
standard therapy with standard therapy alone for treatment of
proximal DVT. This study started in 2013 and is still ongoing [80].
The primary study hypothesis is that PCDT will reduce the in-
cidence of PTS within 2 years by one-third, as assessed using the
Villalta Scale.
Percutaneous mechanical thrombectomy (PMT) devices are
also a minimally invasive adjunctive treatment option for de-
creasing the incidence of PTS. A single-center prospective study by
Engelberger found that ultrasound-assisted CDT yielded a high
rate of venous patency with a low risk of bleeding complications in
patients with ilio-femoral DVT [81]. Karthikesalingam et al. re-
viewed 16 prospective case series including 481 patients who re-
ceived rheolytic, rotational, or ultrasound-assisted PMT [82]. These
various devices all appeared to be safe with no procedure-related
deaths or stroke; the incidence of PE was o1% and bleeding
complications occurred in 6 studies out of 16. This review reported
little substantial evidence to support routine use of PMT over CDT
alone. Despite the increasing evidence for use of endovascular
techniques for acute DVT, the 10th Edition of the Antithrombotic
Guideline did not change the level of recommendation (Grade 2C)
[61].
5.4. Surgical thrombectomy
Surgical thrombectomy provides an improved patency rate and
a decreased incidence of PTS. Plate et al. evaluated the 10-year
outcome of patients with ilio-femoral DVT who were randomly
assigned to receive either conventional anticoagulation or
thrombectomy combined with a temporary arteriovenous ﬁstula
and anticoagulation. They found that iliac vein occlusion was more
common in the medically treated group than in the surgically
treated group (59% vs. 17%, po0.05) [83].6. Management of PTS
Currently, treatment options for PTS are limited, and no uni-
form protocols have been established.
6.1. Use of a compression device
ECSs have been considered a ﬁrst-line treatment option for PTS.
However, the beneﬁt of ECSs for amelioration of PTS symptoms
has been widely debated. Patients who have PTS are usually given
stockings with a higher strength (30–40 mmHg). Ginsberg et al.
randomly stratiﬁed 35 patients with symptomatic PTS into an
active 30–40 mmHg compression stockings group and a placebo
stockings group and found no signiﬁcant inter-group difference in
the proportion of treatment failure (61.1% vs. 58.8%, p40.99) [84].
On the other hand, Volikova et al. used high-frequency ultrasound
to investigate the effect of compression on dermal thickness in
patients with PTS [85]. They found that patients with venous ul-
cers had a signiﬁcantly greater dermal thickness than patientswithout ulcers (p¼0.002). However, dermal thickness returned to
the normal control level after compression therapy. They also
found a cutoff of 1.985 mm for prediction of severe PTS with a
positive predictive value of 46.9% and a negative predictive value
of 90.3%.
Intermittent pneumatic compression (IPC) can counteract the
elevated venous pressure in patients with established PTS. For PTS
patients in whom ECSs are ineffective, an IPC device can be an
alternative for moderate or severe cases. Among patients with
venous leg ulcers, the use of IPC for 4 h daily combined with
standard wound care and compression was reported to sig-
niﬁcantly promote wound healing (p¼0.009) [86]. Another small
clinical study involving 15 patients with PTS revealed that IPC to
40 mmHg relieved severe edema in some cases [87]. In a study of
the mechanisms of ﬁbrinolytic enhancement with IPC, Comerota
et al. found a striking increase of ﬁbrinolytic activity at 180 min in
both normal subjects and PTS patients (p¼0.01–0.001) [88].
However, both baseline and stimulated ﬁbrinolytic activity were
decreased in PTS patients.
The Venowave was developed to assist venous return for
treatment of severe PTS. O’Donnell et al. carried out a two-center,
placebo-controlled double-blind crossover RCT involving 32 pa-
tients who were divided into a Venowave arm and a control device
arm [89]. Two eight-week periods of treatment were separated by
a four-week washout period, and clinical success was achieved in
31% of patients in the Venowave arm compared with 13% in the
control device arm (p¼0.11). Similarly, neuromuscular electro-
stimulation is known to enhance lower limb blood perfusion. Ja-
wad et al. compared changes in blood ﬂow by applying either a
neuromuscular electrostimulation device (geko™) or IPC devices,
and found that the former was superior to the latter in increasing
both venous and arterial blood volume by 30% (po0.001) [90].
Grifﬁn et al. measured changes blood ﬂow in axial deep veins with
and without the geko™ [91]. Increases in peak velocity were found
in the peroneal vein (216%), the posterior tibial vein (112%) and the
gastrocnemius vein (137%) in the geko™ group. Similarly, the
ejected volume per stimulus was increased by 113% in the per-
oneal vein, 38% in the posterior tibial vein and 50% in the gas-
trocnemius vein. Consequently, The National Institute for Health
and Care Excellence (NICE) in England has endorsed use of the
geko™ device for individuals with a high risk of VTE when stan-
dard methods of prophylaxis are unsuitable or cannot be used
[92]. However, further studies will be required to clarify whether
such hemodynamic enhancement with a neuromuscular electro-
stimulator could also be beneﬁcial for patients with PTS [93].
6.2. Pharmacologic therapy
The effect of pharmacologic therapy for patients with PTS is
unclear. A review by Cochrane evaluated the effect of pentoxifyl-
line for venous leg ulcers in 12 studies involving a total of 864
patients. The conclusion of the review was that pentoxifylline is
more effective than placebo for ulcer healing (RR 1.70 95% CI 1.14–
2.24), that pentoxifylline combined with compression is more ef-
fective than placebo combined with compression (RR 1.56 95% CI
1.14–2.13), and that pentoxifylline with no compression is more
effective than placebo or no treatment (RR 2.25 95% CI 1.49–3.39).
In contrast, the Cochran Vascular Group reviewed three studies
with a total of 233 participants who were treated with rutosides
(platelet aggregation inhibitors) [94]. Compared with ECSs or
placebo, there were no signiﬁcant differences in the improvement
or deterioration of PTS symptoms in patients treated with ruto-
sides; the odds of an improvement in PTS in patients treated with
rutosides relative to patients treated with ECSs was 29%. However,
the review found no evidence that rutosides were superior to the
use of placebo or ECSs. A meta-analysis of ﬁve studies evaluating
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found that complete ulcer healing occurred in 61% of patients in
the MPFF group and 48% of control patients (RR 32% 95% CI 3–70%).
Finally, a Cochrane review evaluated the use of horse chestnut
seed extract for treatment of chronic venous insufﬁciency, and
concluded that it did relieve symptoms including leg pain and
edema in the short term [95].
6.3. Exercise
In a two-center RCT conducted by Kahn et al., patients with
mild to moderate PTS were randomized to receive a six-month
exercise training program or control treatment [96]. Exercise
training was associated with improvement in the Venous In-
sufﬁciency Epidemiological and Economic Study Quality of Life
(VEINES-QOL) scores (6.075.1 for the exercise group versus
1.477.2 for the control group, 95% CI 0.54–8.7; p¼0.027) and
improvement in the Villalta scale scores (3.673.7 versus the
control group; mean change 1.674.3, 95% CI 4.6 to 0.6;
p¼0.14). It was concluded that exercise training might improve
PTS. A large RCT will be necessary to conﬁrm whether exercise
training could be potentially useful for amelioration of PTS
symptoms.
6.4. Stent placement for chronic obstructive venous segment
Several investigators have reported the efﬁcacy of venous
stenting for chronic obstructive venous segment in terms of clin-
ical symptoms, venous outﬂow and calf muscle pump function
[97–99]. Raju reviewed peer-reviewed reports of iliac vein stenting
that involved 41500 patients [100]. All of the reports were for
single-arm retrospective series. In these studies, iliac vein stenting
achieved a 90–100% patency rate for non-thrombotic iliac vein
lesions (NIVL) and 74–89% for PTS, with a venous ulcer healing rate
of 58–90%. Wen-da et al. conducted a systematic review of 14
studies of stent placement therapy for obstructive CVD [101], and
found that the rate of ulcer healing was 70.3% (95% CI 59.0–79.5%)
for PTS and 86.8% (95% CI 69.6–95.1%) for NIVL. The ulcer recur-
rence rate was 8.7% (95% CI 5.3–14.0%), and the primary, assisted
primary, and secondary patency rates were 91.4%, 95.0%, and
97.8%, respectively, at 12 months and 77.1%, 92.3%, and 94.3%, re-
spectively, at 36 months. Although, the patency rates for PTS were
lower, stents may be relatively effective in patients with PTS.
6.5. Percutaneous prosthetic vein valve placement
Evaluation of prosthetic vein valves for deep venous valve in-
sufﬁciency is still limited. In an animal study, De Borst percuta-
neously delivered a venous valve prosthesis (glutaraldehyde-ﬁxed
bovine vein sutured to a self-expanding Nitinol stent) via the
porcine extrajugular vein into the iliac vein [102]. The animals
were randomly given either vitamin K antagonists or a combina-
tion of aspirin and clopidogrel. Among 8 valves, 7 were patent (3
competent) in animals receiving vitamin K antagonists, whereas
5 out of 10 valves were patent (3 competent) in animals receiving
aspirin and clopidogrel. After a phase I trial [103], the prosthesis
was redesigned (valve with pericardial tissue, increasing the radial
stiffness of the Nitinol stent, and incorporating a heparin coating).
Phase II clinical trials of the new prosthesis are being planned in
Europe and the United States.
Pavcnik et al. also developed a percutaneously deployed venous
valve prosthesis. The ﬁrst-generation valve was composed of Ni-
tinol or stainless steel wires and a sheath made of small-intestinal
submucosa. Using a sheep model, 25 valves were placed into the
jugular veins and 88% exhibited good function. The remaining 12%
had decreased function due to valve tilting [104]. The prostheticvenous valves were also placed in 3 patients without subsequent
complications. The second-generation prosthetic valve was mod-
iﬁed to prevent tilting, and this achieved a success rate of 92%
[105,106]. The third-generation valve was further modiﬁed to
prevent possible contact of the leaﬂet portion with the vein wall
and to ensure continuous leaﬂet coaptation. The authors also
conducted a feasibility study with a percutaneously deployed au-
tologous venous valve in an ovine model, and noted that patency
and competency were retained for 3 months [107].
6.6. Venous valve surgery
To date, numerous techniques for venous valve reconstruction
have been reported, including both internal and external venous
valve repair, valve transposition, and venous valve transplantation
[108–118]. A detailed review of venous valve surgery appeared in
the ﬁrst issue of this Journal [119]. However, the efﬁcacy of these
techniques for ulcer healing has been reported to be signiﬁcantly
lower in patients with PTS than these with primary valvular in-
sufﬁciency [120]. In contrast, Maleti and Lugli proposed a new
neovalve construction technique involving ﬂap creation [121]. In
17 limbs treated by neovalve construction, postoperative surveil-
lance demonstrated a signiﬁcant improvement in venous hemo-
dynamics. Lugli et al. further modiﬁed their technique, and found a
signiﬁcant improvement in valvular competency [122]. In 2011,
Maleti and Perrin described the results of various venous valve
reconstruction techniques [123], and concluded that, in terms of
clinical outcome, Maleti neovalve construction achieved better
results than valvuloplasty, valve transposition or valve
transplantation.7. Conclusion
PTS is a common problem following DVT, and its clinical fea-
tures range from minimum symptoms to disabling venous ulcers.
In order to reduce the incidence of PTS, early clot lysis may be the
key to restoring patency and potentially preserving valve function.
Recent advances in endovascular catheter procedures provide
better clot lysis than standard oral anticoagulant therapy. How-
ever, DOACs have been proven to show earlier lytic efﬁcacy than
vitamin K antagonists in experimental models. Extended antic-
oagulation with DOACs may be promising for reducing the risk of
PTS in comparison with standard anticoagulant therapy. The ap-
plication of ECSs after DVT has been widely accepted to prevent
the development of PTS. Currently, however, the efﬁcacy of ECSs
for preventing PTS is controversial. For patients with established
PTS, the treatment options are still limited. The use of a neuro-
muscular electrostimulator device may reduce the chronic symp-
toms of PTS. Stenting of the chronic obstructive iliac venous seg-
ment improves venous outﬂow and clinical symptoms. Develop-
ment of bioprosthetic venous valves and related clinical trials are
still ongoing. Although attempts at preventing PTS using open
venous surgery have met with limited success, a new neovalve
construction technique has demonstrated better clinical outcomes
than previously reported venous valve surgery. These new devel-
opments may be beneﬁcial for reducing the incidence of PTS in the
future.Conﬂict of interest
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